Search results for "SF3B1"

showing 4 items of 4 documents

SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance.

2021

Aim: Because mutations of splicing factor 3B subunit-1 (SF3B1) have been identified in 4% of pancreatic ductal adenocarcinoma (PDAC) patients, we investigated the activity of new potential inhibitors of SF3B1 in combination with gemcitabine, one of the standard drugs, in PDAC cell lines. Methods: One imidazo[2,1-b][1,3,4]thiadiazole derivative (IS1) and three indole derivatives (IS2, IS3 and IS4), selected by virtual screening from an in-house library, were evaluated by the sulforhodamine-B and wound healing assay for their cytotoxic and antimigratory activity in the PDAC cells SUIT-2, Hs766t and Panc05.04, the latter harbouring the SF3B1 mutations. The effects on the splicing pattern of pr…

DrugPancreatic ductal adenocarcinomaKey genesbusiness.industrymedia_common.quotation_subjectPancreatic ductal adenocarcinoma gemcitabine indole derivatives anti-proliferative activity antimigratory activity SF3B1 RON hENT1Affect (psychology)medicine.diseaseGemcitabineMetastasisPancreatic cancerCancer researchmedicinebusinessmedia_commonmedicine.drugCancer drug resistance (Alhambra, Calif.)
researchProduct

SANS (USH1G) regulates pre-mRNA splicing by mediating the intra-nuclear transfer of tri-snRNP complexes

2021

Abstract Splicing is catalyzed by the spliceosome, a compositionally dynamic complex assembled stepwise on pre-mRNA. We reveal links between splicing machinery components and the intrinsically disordered ciliopathy protein SANS. Pathogenic mutations in SANS/USH1G lead to Usher syndrome—the most common cause of deaf-blindness. Previously, SANS was shown to function only in the cytosol and primary cilia. Here, we have uncovered molecular links between SANS and pre-mRNA splicing catalyzed by the spliceosome in the nucleus. We show that SANS is found in Cajal bodies and nuclear speckles, where it interacts with components of spliceosomal sub-complexes such as SF3B1 and the large splicing cofact…

ProteomicsAcademicSubjects/SCI00010Ribonucleoprotein U4-U6 Small NuclearSF3B1 GeneMass Spectrometry0302 clinical medicineRNA Small NuclearRNA PrecursorsIn Situ Hybridization FluorescenceRibonucleoprotein0303 health sciencesChemistryRibonucleoproteins Small NuclearImmunohistochemistryCell biologyDNA-Binding Proteinsmedicine.anatomical_structureGene Knockdown TechniquesRNA splicingRNA Splicing FactorsUsher SyndromesSpliceosomeCoiled BodiesNerve Tissue ProteinsBiologyMinor Histocompatibility Antigens03 medical and health sciencesMicroscopy Electron TransmissionRNA and RNA-protein complexesGeneticsmedicineHumanssnRNPEye ProteinsGeneCell Proliferation030304 developmental biologyCell NucleusRNAmedicine.diseasePhosphoproteinsCiliopathyAlternative SplicingCell nucleusHEK293 CellsCajal bodyCytoplasmSpliceosomesNucleus030217 neurology & neurosurgeryTranscription FactorsNucleic Acids Research
researchProduct

Caracterización molecular de la anemia refractaria con sideroblastos en anillo mediante un panel de secuenciación de segunda generación

2019

Los síndromes mielodisplásicos (SMD) son un grupo heterogéneo de neoplasias hematológicas que presentan citopenias, mielodisplasia, hematopoyesis ineficaz y un riesgo variable de transformación a leucemia mieloide aguda (t-LMA). Los SMD con sideroblastos en anillo (SMD-SA) constituyen aproximadamente el 10-12% de todos los SMD y en médula ósea muestran SA, eritroblastos con depósitos anormales de ferritina, en porcentaje igual o superior al 5%. El objetivo terapéutico en los SMD-SA es mejorar las citopenias y su sintomatología, en especial el síndrome anémico. La administración de eritropoyetina y el soporte transfusional con concentrados de hematíes son las opciones terpéuticas de primera …

UNESCO::CIENCIAS DE LA VIDA::Biología molecularazacitidina:CIENCIAS MÉDICAS ::Medicina interna::Hematología [UNESCO]SF3B1DNMT3Asecuenciaciónsíndromes mielodisplásicossideroblastos en anillo:CIENCIAS DE LA VIDA::Biología molecular [UNESCO]UNESCO::CIENCIAS MÉDICAS ::Medicina interna::Hematología
researchProduct

DESIGN OF SF3B1 SUBUNIT MODULATORS OF THE SF3B SPLICEOSOME COMPLEX

2022

The subject of this dissertation is the search for new therapeutic strategies for pancreatic cancer and aims to implement a Drug Discovery process for the rational design and synthesis of molecules active in the modulation of pathways related to the regulation of pre-mRNA splicing process. This research project is the result of a joint PhD between the University of Palermo, Italy, and the Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands. It integrates complementary skills in pharmaceutical chemistry and translational cancer research with a special focus on the rational design of new anticancer compounds potentially active on SF3B1 (Splicing Factor 3B …

splicing4]thiadiazole compoundsdrug resistancehuman equilibrative nucleoside transporter-13mesotheliomaSF3B1gemcitabinepancreatic ductal adenocarcinoma1-b][1SF3B1 splicing imidazo[21-b][134]thiadiazole compounds pancreatic ductal adenocarcinoma gemcitabine human equilibrative nucleoside transporter-1 drug resistance mesotheliomaimidazo[2
researchProduct